Pre-surgery immunotherapy shows zero recurrence in bowel cancer trial
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
In the NEOPRISM-CRC clinical trial led by UCL and UCLH, 32 patients with stage two or three bowel cancer received up to nine weeks of pembrolizumab before surgery instead of standard post-operative chemotherapy. After 33 months of follow-up, none of the patients experienced a cancer recurrence, whereas about 25% typically relapse within three years with conventional treatment. Additionally, 59% had no detectable disease signs after treatment, and any remaining traces did not grow or spread.
Continue in the app — vote & join in ➔Source: ScienceDaily · via ahirlevel.hu